معرفی
David Caba Molina, MD, MS, MPH is an Assistant Professor in the Department of Surgery, Surgical Oncology Division at Loma Linda University School of Medicine. His clinical and research focus centers on gastrointestinal malignancies and melanoma, with emphasis on surgical innovation and health equity.
Education:
- Doctor of Medicine (MD)
- Master of Science (MS)
- Master of Public Health (MPH)
Research Interests:
Dr. Caba Molina's work spans surgical oncology with deep expertise in colorectal cancer, pancreatic cancer, and melanoma. He investigates treatment outcomes for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), health disparities in safety-net hospitals, and international cancer care infrastructure. His translational research explores molecular mechanisms like duocarmycin analogs and non-coding RNAs in pancreatic cancer, alongside clinical studies on immunotherapy and novel surgical approaches for gastrointestinal stromal tumors.
Publication Trends:
His 14 publications (2019-2025) reveal evolving expertise from robotic pancreatic surgery (2019) to molecular oncology (2024-2025). Recent high-impact work in Annals of Surgical Oncology addresses Medicaid expansion's impact on CRS/HIPEC access, while Cancers and Biochimica et Biophysica Acta publications explore duocarmycin analogs and non-coding RNAs. Over 50% of his output (7/14) emerged in 2024-2025, highlighting accelerated contributions to gastrointestinal cancer therapeutics and health policy.
Scientific Awards:
- No scientific awards mentioned in source materials
Grants and Research Projects:
As Principal Investigator on five funded projects, Dr. Caba Molina addresses critical gaps in surgical oncology. His Castle Biosciences-sponsored trial examines DecisionDx-Melanoma's impact on sentinel lymph node biopsies, while internal LLU grants support pancreatic adenocarcinoma clinical trials, Africa-focused surgical training assessments, and sarcoma biopsy utility studies.
- CBl-2019-SLNBprosp-001: DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions (Castle Biosciences, 2020)
- Phase II trial of preoperative chemo/SBRT for pancreatic adenocarcinoma (LLU Surgery, 2024-2025)
- Africa cancer care training needs assessment (PAACS/COSECSA, 2021-2023)
- Preoperative sarcoma biopsy utility study (LLU Surgery, 2020)
- Gastric/Esophageal cancer databank (LLU Surgery, 2019)
Labs and Teams:
Research appears integrated within Loma Linda University's Department of Surgery infrastructure without dedicated lab mentions; collaborations span Castle Biosciences, PAACS, and COSECSA networks.
